Medexus Pharmaceuticals Inc. (TSE:MDP) Receives Consensus Recommendation of "Buy" from Brokerages

Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) has received a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and four have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is C$5.49.

MDP has been the topic of a number of analyst reports. Raymond James upgraded shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. Ventum Financial upped their price target on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a "buy" rating in a report on Thursday, January 30th. Leede Financial raised shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Stifel Canada downgraded Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Finally, Stifel Nicolaus lowered Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and decreased their price target for the stock from C$6.00 to C$3.45 in a research note on Friday, February 7th.

Medexus Pharmaceuticals Price Performance

Shares of TSE:MDP traded down C$0.04 during trading on Thursday, hitting C$2.76. The company had a trading volume of 18,300 shares, compared to its average volume of 103,961. The stock has a market cap of C$61.79 million, a price-to-earnings ratio of 13.20 and a beta of 1.96. The company has a fifty day simple moving average of C$2.52 and a two-hundred day simple moving average of C$2.88. Medexus Pharmaceuticals has a one year low of C$1.50 and a one year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.